Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07223476 · ClinicalTrials.gov registry record
Treatment Landscape and Real-World Dosing Patterns With CDK4/6 Inhibitors for Breast Cancer in Portugal
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 1,926
- Enrollment target
NCT07223476: Completed study, sponsored by Novartis Pharmaceuticals.
NCT07223476 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,926 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07223476 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 1,926 participants
- Enrollment target
Study Summary
Assess and characterize the real-world cyclin-dependent kinase 4/6 inhibitor (CDKI) use in advanced/metastatic breast cancer (a/mBC), evaluate treatment persistence, and quantify CDKI dose adjustments in Portugal. This study used secondary data from the IQVIA database that collects data from hospital drug consumption. The study included 16 public hospitals across Portugal, for which data on consumption of drugs used in hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) a/mBC treatment was available. Patient selection was based on a set of criteria considering all patients with treatments in the a/mBC setting with use of at least one CDKI from November 2018 to May 2023.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,926 participants |
| Start Date | 2024-03-29 |
| Est. Completion | 2024-07-01 |
What the finished NCT07223476 record still lists
NCT07223476 is an observational study that tracks outcomes without assigning an intervention. Its 1,926 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT07223476 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07223476 about?
NCT07223476 is a clinical study titled "Treatment Landscape and Real-World Dosing Patterns With CDK4/6 Inhibitors for Breast Cancer in Portugal". Assess and characterize the real-world cyclin-dependent kinase 4/6 inhibitor (CDKI) use in advanced/metastatic breast cancer (a/mBC), evaluate treatment persistence, and quantify CDKI dose adjustments in Portugal. This study used secondary data from the IQVIA database that collects data from hospit...
What is the current status of trial NCT07223476?
This trial is currently completed. The enrollment target is 1,926 participants. The study started on 2024-03-29. Estimated completion is 2024-07-01.
Who is sponsoring clinical trial NCT07223476?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05233150 · 1,932 participants · NA
Child-Adult Relationship Enhancement in Primary Care (PriCARE) / Criando Niños Con CARIÑO (CARIÑO)
- NCT06058455 · 1,920 participants · NA
An Evaluation of an Online Sexual Assault Resistance Program (IDEA3)
- NCT05174169 · 1,912 participants · Phase 2
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
- NCT06799117 · 1,912 participants · NA
Adaptive Decision Support for Addiction Treatment Master
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI